Stephen J. Thomas's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (4)
BACKGROUND BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approve...
Background: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional approval worldwide. At the time of authorization, data beyond 2...
Background
Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socialization, and contribute to herd immunity.
Methods
In...
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently.
Methods
Download a PDF of the Research Summary.
In an ongoing multinational, placebo-controlled,...
Citations
... Population wise, as far as the effectiveness of rapid, mass vaccinations to SARS-CoV-2 is concerned, the high rate of inoculation within the community was proved to be a competent tool to curb the spread of the virus (Paetzold et al. 2022). However, the decline of vaccine efficacy in preventing viral transmission over time, is one of the leading concerns regarding vaccine protection in the long term (Daković et al. 2022;Thomas et al. 2021). Moreover, the occurrence of new variants of SARS-CoV-2, such as Delta, is yet another factor that was reported to lower the vaccine-induced immunity against SARS-CoV-2 infection (Keehner et al. 2021;Nanduri et al. 2021;Rivasi et al. 2022). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/793707481673728-1566246018073_Q64/Edson-Moreira-Jr.jpg)
... They concluded that in 16 years old and above, two doses of BNT162b2 inferred 95% protection against COVID-19 [26]. However, according to another pivotal study, four months after the second dose, efficacy declined by an average of 6% every two months, from 96.2% to 83.7% [58]. In addition, a new study suggests that two doses of the Pfizer-BioNTech vaccine were less effective against a more contagious strain. ...
... and Beta (B.1.351) variants) in more than 90% in children and adolescents aged 5-11, 12-15, and 16-17 years [1][2][3]. At the time when vaccination against SARS-CoV-2 was initiated, the B.1.617.2 (Delta) variant was dominant. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272392085831715-1441954742566_Q64/William-Gruber-3.jpg)
... The SARS-CoV-2 mRNA vaccine is highly effective in preventing the onset and reducing the severity of the novel coronavirus infection, and vaccination is recommended to prevent the spread of the infection (1,2). However, cases of immune-mediated inflammatory diseases caused by SARS-CoV-2 mRNA vaccine have been reported (3)(4)(5)(6)(7). ...
